Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

PRESCRIPTIONS handed out for semaglutide - a drug used to treat diabetes and more commonly known as Ozempic - more than... Local News News Barnsley South Yorkshire ...

Experts warn Ozempic and Mounjaro may cause sudden, irreversible blindness as patients report vision loss after taking the weight loss drugs.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...